Adbry Autoinjector Delivers Eczema Dose in One Shot

Adults using Adbry for moderate-to-severe eczema can now get the full 300 mg dose in a single injection.

Updated on Nov. 6, 2026 in Asthma

Plain pen-shaped autoinjector resting on a pale ceramic bathroom counter beside a folded white towel, softly lit by window daylight.
LEO Pharma's Adbry eczema treatment can now be delivered as one 300 mg injection, after the FDA approved a new 2 mL autoinjector. AI Illustration. Upload story photo >

The FDA has approved a new 2 mL autoinjector for LEO Pharma's Adbry, a biologic treatment for moderate-to-severe eczema. The device delivers the 300 mg dose in a single injection, where patients previously needed two separate 1 mL injections, a change relevant to people who self-administer the therapy at home.

Why it matters

Biologic therapies have traditionally been given at a clinic through intravenous infusion, so large-volume autoinjectors that allow home self-administration can reduce trips to the clinic and make ongoing treatment more manageable for people with chronic skin disease. The approval reflects a broader push to move more biologic treatments into the home setting.

The approval concerns a device presentation rather than a new efficacy finding, and the available details describe the dosing format change only. The source does not report trial design, sample size, or comparative outcome data for the autoinjector.

The players

LEO Pharma

A Danish pharmaceutical company focused on dermatology, whose treatments include Adbry for eczema.

U.S. Food and Drug Administration

The federal agency responsible for approving drugs and medical devices, including the autoinjector for Adbry.

The details

The new autoinjector holds 2 mL of solution, enough to deliver the full 300 mg dose in one injection instead of splitting it across two 1 mL syringes. Fewer injections per dose means one administration step rather than two, which is the practical change for patients who inject the drug themselves. Large-volume autoinjectors of this kind are part of a shift toward home administration of biologic medicines that have historically required infusion visits.

Timeline

  1. The FDA approved the new 2 mL autoinjector for Adbry in October 2026.

Health Landscape

Biologic treatments for chronic inflammatory skin disease have typically depended on clinic-based infusions, which limits access and adds visit burden. Large-volume autoinjectors are part of a wider movement to move these therapies into home settings, and this approval adds one more option to that trend.

If you or someone you care about receives a biologic injection for a chronic skin condition, the single-injection format could mean one fewer step per dose. Anyone considering a switch to home injections should raise the question with their prescribing physician to see whether it fits their treatment plan.

The takeaway

Home-administered biologics are expanding, and a single-injection format can simplify ongoing treatment for eligible patients. Discuss with your physician whether an autoinjector option is appropriate for your care.

Further reading

For related context on managing chronic conditions with long-term treatments, browse our Asthma coverage.

Source note: This article includes information reported by Manufacturingchemist.